New Chief of Renal Pathology - Dr. Evan Farkash

We are pleased to welcome Dr. Evan Farkash as the new section chief for Renal Pathology as of September 1, 2020. 

Now Offering PD-L1 Testing

MLabs is now offering PDL-1 testing for Metastatic triple-negative breast cancer (TNBC) whose tumors express PD-L1.

Welcoming New Director of Anatomic Pathology

The Department Pathology and Michigan Medicine Laboratories is pleased to announce and welcome Dr. Liron Pantanowitz, our new A. James French Professor and Director of Anatomic Pathology. 

NOW AVAILABLE: New NGS Myeloid Panel! 

NOW AVAILABLE: NGS Myeloid Panel!  MLabs is excited to announce the addition of our new NGS Myeloid
Panel: For any myeloid or suspected myeloid neoplasm.

Michigan Medicine Ranked No. 5 Hospital in the U.S., No 15 in the World by Newsweek

Michigan Medicine has earned the No. 15 spot in Newsweek’s 2020 World’s Best Hospitals list.

The institution also came in fifth in the United States and was named top hospital in Michigan.

COVID-19 IgG Serology Testing Now Available!

Serology testing for SARS-CoV-2 is now available for ordering. A separate process for testing and screening of health care workers and Michigan Medicine affiliates will be communicated in the coming weeks. 

USCAP 2020 Conference

USCAP has its eyes on you as you navigate the exhibit hall, posters, platform sessions special courses, Long Course on Major Advances in the Diagnosis and Management of Breast Diseases, short courses, interactive microscopy courses...

FSP Annual Meeting 2020

Once again,  MLabs will be exhibiting at The FSP’s 46th Annual Pathology Conference: Updates and Practical Approaches in Pathology is designed to provide pathologists with education surrounding...

ASHG 2019 Conference

The ASHG 2019 Annual Meeting provides a forum for the presentation and discussion of cutting-edge science in all areas of human genetics. It will be held in... 

MLABS offers NGS to detect PIK3CA mutation targeted by New Metastatic Breast Cancer Treatment

Many patients living with metastatic breast cancer (mBS) now have a new treatment option.

In May 2019, the FDA approved a new targeted therapy, alpelisib (Piqray®). An oral medication intended to be used in combination with fulvestrant (Faslodex®), Piqray® is...